STOCK TITAN

Akari Therapeutics plc ADR (0.01 USD) - AKTX STOCK NEWS

Welcome to our dedicated page for Akari Therapeutics plc ADR (0.01 USD) news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics plc ADR (0.01 USD) stock.

Akari Therapeutics Plc (Nasdaq: AKTX) is a clinical-stage biopharmaceutical company developing innovative treatments for autoimmune and inflammatory diseases. The company's lead asset, nomacopan, is a bispecific recombinant inhibitor targeting complement C5 and leukotriene B4 (LTB4) pathways. This dual-action therapeutic is currently being investigated in a Phase 3 trial for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), a rare and serious complication with high mortality rates. Nomacopan has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, as well as orphan drug designation from the European Commission.

Akari's pipeline also includes PAS-nomacopan, a long-acting version of the drug designed for the treatment of geographic atrophy (GA), a leading cause of blindness. PAS-nomacopan is in the final stages of pre-clinical development and aims to offer extended dosing intervals with potentially improved safety and efficacy compared to existing therapies.

The company's strategic focus recently expanded through a definitive merger agreement with Peak Bio Inc. (OTC: PKBO), expected to close in Q3 2024. This merger will create a robust pipeline featuring both Akari's autoimmune and inflammatory disease therapeutics and Peak Bio's antibody-drug conjugate (ADC) platform technology for cancer treatment.

Financially, Akari is focused on operational efficiency and value creation. The company has taken significant measures to reduce costs and secure funding, including a successful private placement raising approximately $7.6 million. Dr. Samir R. Patel, an experienced life sciences entrepreneur, has recently been appointed Interim CEO to lead the company through this transformative phase. Dr. Patel's compensation is solely equity-based, aligning his interests with those of the shareholders.

For more information, visit akaritx.com.

Rhea-AI Summary

Akari Therapeutics, Plc (Nasdaq: AKTX) is set to participate in ARVO 2023 from April 23 to 27 in New Orleans. The event gathers around 10,000 professionals in vision research to discuss advancements in the field. Akari’s primary focus is on its investigational drug, nomacopan, a bispecific inhibitor targeting complement C5 and leukotriene B4, currently in pre-clinical development for geographic atrophy. Akari is also advancing nomacopan through a Phase 3 trial for pediatric HSCT-TMA, supported by FDA designations including Orphan Drug and Fast Track. The company aims to connect with researchers and potential partners at ARVO 2023 to drive innovation in autoimmune and inflammatory disease therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
conferences
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) announced a case study presentation titled Clinical Response to Nomacopan in the Paediatric HSCT-TMA Setting, scheduled for April 23, 2023, during the European Society for Blood and Marrow Transplantation (EBMT) in Paris. Nomacopan, an investigational bispecific inhibitor, is currently in Phase 3 clinical trials targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company plans to advance into pivotal Part B trials later this year. Akari holds multiple FDA designations for nomacopan and is developing it for both pediatric and adult indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.09%
Tags
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) has secured approximately $4 million in gross proceeds through a direct offering involving institutional and accredited investors, including its Board of Directors. The company will issue around 26.67 million American Depository Shares (ADSs) at a price of $0.15 per ADS. Proceeds will fund two key pipeline initiatives: advancing a Phase 3 trial for nomacopan in severe pediatric conditions and a preclinical study for geographic atrophy. The offering excludes warrants and is expected to close on March 31, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.2%
Tags
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) has announced that regulatory agencies in Poland and the U.K. approved amendments to its Investigational Medicinal Product Dossier and Clinical Trial Authorisation for the third-generation manufacturing process of nomacopan, which significantly boosts its yield by at least 5-fold. This enhancement is set to improve cost efficiencies as Akari moves into pivotal Part B of the Phase 3 clinical trial for nomacopan, targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The trial includes sites in Poland, the U.K., and the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
-
Rhea-AI Summary

The 'Asthma Pipeline Insight – 2023' report by DelveInsight reveals a dynamic landscape in asthma therapies, highlighting over 90 active pharmaceutical players developing more than 95 pipeline treatments. Key companies include GlaxoSmithKline, AstraZeneca, and Verona Pharma. Notably, dexpramipexole received an Innovation Passport from the UK's MHRA and is entering Phase III trials. Additionally, Pulmatrix, Inc. initiated a Phase IIb trial for PUR1900, targeting Allergic Bronchopulmonary Aspergillosis. Olatec Therapeutics secured $40 million in Series A funding to advance dapansutrile into clinical development. This report offers insights into asthma clinical trials, therapeutic assessments, and drug mechanisms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) has made significant strides in its Phase 3 Part A clinical trial of nomacopan for pediatric HSCT-related thrombotic microangiopathy (HSCT-TMA). A case study presented on February 16 at a major transplantation conference highlighted the positive outcomes for a 6-year-old patient who showed improvement after receiving nomacopan treatment.

Notably, the patient achieved critical therapeutic milestones, including normalization of key biomarkers and resolution of related health complications. Nomacopan is recognized as a promising therapy in a field lacking approved options for severe cases, potentially addressing an 80% mortality rate in untreated patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.73%
Tags
Rhea-AI Summary

Akari Therapeutics announced progress on its pre-clinical program for long-acting PAS-nomacopan, targeting geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). An Investigational New Drug (IND) application is set for submission to the FDA in the first half of 2024. The company filed a composition of matter patent application for long-acting versions, providing protection until 2042. The new PAS-nomacopan versions exhibit significant improvements, allowing for increased dosing intervals beyond three months, potentially reducing the need for frequent intravitreal injections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) has announced the progression into Part B of its Phase 3 clinical trial for nomacopan, targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Following favorable FDA feedback indicating that pharmacokinetic/pharmacodynamic data from Part A aligns with predictions, Akari will advance its study for patients aged 2 to <18 years. To support this, a new pipeline program for adult HSCT-TMA treatment with nomacopan is being initiated, given the larger adult patient population. The company's prompt actions highlight a commitment to addressing unmet medical needs in both pediatric and adult demographics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary

The paroxysmal nocturnal hemoglobinuria (PNH) market is projected to reach USD 1,100 million in 2021, with anticipated growth driven by rising cases and new therapies from major companies like Hoffmann-La Roche, Alexion, and Novartis. DelveInsight's report indicates approximately 12K prevalent cases in the 7MM (U.S., EU-4, U.K., Japan) as of 2021. Key pipeline therapies include Crovalimab and Iptacopan. Despite advancements, challenges like continuous hemolysis and the impending expiration of eculizumab patents in 2024 and 2027 could impact market dynamics. This report covers market trends through 2032, focusing on treatment efficacy, barriers, and emerging drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
Rhea-AI Summary

On January 4, 2023, Akari Therapeutics (Nasdaq: AKTX) announced that President and CEO Rachelle Jacques will present at the Biotech Showcase 2023 on January 9 at 9 am ET. The presentation will cover significant updates on two pipeline programs: a Phase 3 trial of nomacopan for treating severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program for long-acting PAS-nomacopan targeting geographic atrophy. Akari is focused on therapies for autoimmune and inflammatory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
conferences

FAQ

What is the current stock price of Akari Therapeutics plc ADR (0.01 USD) (AKTX)?

The current stock price of Akari Therapeutics plc ADR (0.01 USD) (AKTX) is $0.97 as of December 20, 2024.

What is the market cap of Akari Therapeutics plc ADR (0.01 USD) (AKTX)?

The market cap of Akari Therapeutics plc ADR (0.01 USD) (AKTX) is approximately 26.5M.

What is the focus of Akari Therapeutics?

Akari Therapeutics focuses on developing innovative therapies for autoimmune and inflammatory diseases, including severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and geographic atrophy (GA).

What is nomacopan?

Nomacopan is Akari's lead drug, a bispecific recombinant inhibitor targeting complement C5 and leukotriene B4 (LTB4) pathways. It is currently in Phase 3 clinical trials for treating HSCT-TMA.

What designations has nomacopan received?

Nomacopan has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, as well as orphan drug designation from the European Commission.

What is PAS-nomacopan?

PAS-nomacopan is a long-acting version of nomacopan, currently in pre-clinical development for treating geographic atrophy (GA), a leading cause of blindness.

What are the recent developments at Akari Therapeutics?

Recent developments include a merger agreement with Peak Bio Inc., raising $7.6 million in a private placement, and appointing Dr. Samir R. Patel as Interim CEO.

What is the significance of the merger with Peak Bio?

The merger is expected to combine Akari's therapeutic pipeline with Peak Bio's ADC platform technology for cancer treatment, expanding the company's capabilities and market potential.

How is Dr. Samir R. Patel compensated?

Dr. Samir R. Patel's compensation as Interim CEO is solely equity-based, aligning his interests directly with those of Akari's shareholders.

What financial measures has Akari taken recently?

Akari has implemented a reduction-in-force to cut costs and has successfully raised $7.6 million through a private placement to fund its operations and strategic initiatives.

What is the timeline for the merger with Peak Bio?

The merger with Peak Bio is expected to close in the third quarter of 2024, subject to customary closing conditions and shareholder approvals.

Where can I find more information about Akari Therapeutics?

For more information, visit Akari Therapeutics' website at akaritx.com.

Akari Therapeutics plc ADR (0.01 USD)

Nasdaq:AKTX

AKTX Rankings

AKTX Stock Data

26.47M
20.19M
11.91%
0.51%
0.18%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON